AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial

Peer Review reports

Original Submission
27 May 2020	Submitted	Original manuscript
28 May 2020	Reviewed	Reviewer Report - Kirsty Loudon
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
30 May 2020	Editorially accepted
19 Jun 2020	Article published	10.1186/s13063-020-04473-1

Back to article page